Skip to main content

Table 2 Hazard ratios for the primary outcome based on different GA variability metrics

From: Visit-to-visit variability of glycated albumin was associated with incidence or progression of lower extremity atherosclerotic disease

 

GA variability indicators tertiles

P value for trend

Per 1 unit increase

T1

T2

T3

CV

 < 7.35

7.35–12.47

 ≥ 12.48

 No. of participants

144

145

147

 No. of cases

31

32

49

 Person-years

510

507

475

 Age and sex-adjusted HRs

1.00

1.02 (0.62–1.68)

1.74 (1.10–2.73)

0.019

1.03 (1.01–1.06)

 Multivariable adjusted HRs

1.00

1.06 (0.65–1.75)

1.71(1.07–2.73)

0.042

1.03 (1.01–1.06)

VIM

 < 0.61

0.61–1.12

 ≥ 1.13

 No. of participants

146

144

146

 No. of cases

32

31

49

 Person-years

521

521

451

 Age and sex-adjusted HRs

1.00

0.95 (0.58–1.57)

1.85 (1.19–2.89)

0.004

1.40 (1.12–1.76)

 Multivariable adjusted HRs

1.00

0.99 (0.60–1.64)

1.65 (1.02–2.67)

0.050

1.32 (1.03–1.69)

ARV

 < 1.75

1.75–3.29

 ≥ 3.30

 No. of participants

145

146

145

 No. of cases

29

33

50

 Person-years

510

523

460

 Age and sex-adjusted HRs

1.00

1.11 (0.67–1.82)

1.97 (1.24–3.12)

0.005

1.10 (1.03–1.18)

 Multivariable adjusted HRs

1.00

1.08 (0.64–1.81)

1.81 (1.08–3.04)

0.032

1.07 (1.01–1.15)

  1. Multivariable adjustments included diabetes duration, smoking status, eGFR, HDL, aspirin, and mean HbA1c